Puneet Souda, an analyst from Leerink Partners, reiterated the Buy rating on Thermo Fisher. The associated price target is $500.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Puneet Souda’s rating is based on a combination of factors that suggest a positive outlook for Thermo Fisher’s stock. The company recently adjusted its long-range plan (LRP) for organic growth, setting a new target of over 7%, which was a strategic move that seemed to boost investor confidence. This adjustment, announced earlier than expected, has set a foundation for potential stock recovery, indicating that the company is positioning itself for future growth.
Moreover, despite some challenges in the early-stage discovery market, Thermo Fisher is benefiting from strong late-stage pharma and biotech trial activities. The company’s management has also provided a new framework for 2026 and 2027, projecting organic growth rates and EBIT margin expansion that align with or exceed market expectations. These strategic plans, along with a positive outlook on pharma spending and R&D intensity, underpin Souda’s Buy rating, reflecting confidence in Thermo Fisher’s ability to navigate current market conditions and achieve long-term growth.
Souda covers the Healthcare sector, focusing on stocks such as Quanterix, Exact Sciences, and Illumina. According to TipRanks, Souda has an average return of -10.3% and a 30.51% success rate on recommended stocks.
In another report released yesterday, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $523.00 price target.